Sun Pharma Schedules 34th AGM for July 31, Sets Record Date for ₹5 Final Dividend
Sun Pharma will hold its 34th AGM on July 31, 2026, via VC. The Record Date for a ₹5 final dividend for FY25-26 is July 7, 2026. Dividend payment is expected by August 7, 2026. Shareholders must submit TDS documents by July 7, 2026.
This is a standard procedural announcement regarding the AGM and dividend, which are expected events for shareholders and do not represent a material change in the company's business operations or financial performance.
The announcement is a routine corporate update regarding the AGM and dividend payment, with no significant positive or negative financial news.
Sun Pharmaceutical Industries Limited has announced the details for its 34th Annual General Meeting (AGM), scheduled to be held on Friday, 31 July 2026, at 4:00 p.m. (IST) through Video Conferencing (VC).
The company will dispatch the Notice convening the AGM and the Annual Report for the financial year 2025-26 to shareholders in due course. Shareholders are advised to update their contact details with their Depository Participants or the Company's Registrar and Transfer Agent to ensure timely receipt of these documents and dividend credit.
Furthermore, Tuesday, 07 July 2026, has been fixed as the Record Date for determining shareholder entitlement to the final dividend of ₹5 per equity share for the financial year 2025-26. The payment of this final dividend, subject to shareholder approval at the AGM, is scheduled for on or before Friday, 07 August 2026.
Dividends are subject to deduction of tax at source. Shareholders can find TDS guidance and document submission processes on the company's website, www.sunpharma.com. Requisite documents for TDS purposes must be submitted by Tuesday, 07 July 2026, to ensure the correct TDS rate is applied.
What to do with a filing like this
Sun Pharmaceutical Industries Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sun Pharmaceutical Industries Limited. Read the original for the full detail.